Skip to content

Integra LifeSciences IART Balance Sheet Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$236.81M+0.7%$235.05M+1.2%$232.19M+6.5%$217.91M-8.9%$239.1M-3.0%
$28.69M0.0%$28.69M-19.6%$35.69M0.0%$35.69M+4.4%$34.19M+25.7%
$264.41M-5.2%$278.85M+6.4%$262.16M-7.9%$284.51M+12.7%$252.45M-7.3%
$495.04M+0.5%$492.74M+0.7%$489.11M+5.2%$465.13M+4.4%$445.42M+3.8%
$1.17B+1.1%$1.16B+1.4%$1.14B+0.1%$1.14B+3.2%$1.11B+2.4%
$446.88M+0.6%$444.34M+1.6%$437.37M+0.6%$434.82M+2.8%$422.91M+4.2%
$613.25M-0.3%$615.16M0.0%$615.2M-0.2%$616.43M-44.2%$1.11B+0.8%
$1.11B-2.6%$1.13B-2.2%$1.16B-2.4%$1.19B0.0%$1.19B-1.7%
$3.58B-0.7%$3.6B-1.2%$3.65B-0.6%$3.67B-9.5%$4.05B+0.4%
$87.95M-8.1%$95.73M+3.7%$92.31M-0.6%$92.84M+1.7%$91.3M+10.7%
$11.62M+1.4%$11.46M+1.2%$11.33M+2.0%$11.1M+5.4%$10.54M+0.5%
$53.28M$38.75M0.0%$38.75M0.0%$38.75M
$346.85M-23.9%$455.98M+25.3%$364.05M-60.8%$929.81M+1.2%$918.45M-0.4%
$1.75B+1.2%$1.73B+1.2%$1.71B+52.8%$1.12B-0.9%$1.13B+3.7%
$2.54B-0.9%$2.56B-1.9%$2.61B-0.8%$2.63B+4.0%$2.53B+1.5%
240M0.0%240M0.0%240M0.0%240M0.0%240M+26,101%
$418.82M-1.1%$423.44M-0.4%$425.15M-1.3%$430.55M-52.9%$914.62M-2.7%
$1.04B-0.1%$1.04B+0.6%$1.04B-0.1%$1.04B-31.9%$1.52B-1.4%
$3.58B-0.7%$3.6B-1.2%$3.65B-0.6%$3.67B-9.5%$4.05B+0.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Integra LifeSciences's total assets?
Integra LifeSciences (IART) holds $3.6B in total assets, down 11.7% year over year.
How much debt does Integra LifeSciences have?
Integra LifeSciences carries $2.0B in total debt against $1.0B of shareholders' equity, a debt-to-equity ratio of 1.90.
How much cash does Integra LifeSciences have?
Integra LifeSciences holds $236.8M in cash and equivalents.
Can Integra LifeSciences cover its short-term obligations?
Its current ratio is 3.38 — current assets exceed current liabilities.
Where does Integra LifeSciences's balance sheet data come from?
Every line is extracted from Integra LifeSciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.